Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-527-9 | CAS number: 122-19-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
Based on the results of the read across study, the test substance, C18 ADBAC, is considered not to pose reproductive or development concern up to 2,000 ppm (i.e., equivalent to 30.5 to 50.5 mg a.i./kg bw/day and 48 to 61.5 mg a.i./kg bw/day for the F0 and F1 generation respectively).
Link to relevant study records
- Endpoint:
- two-generation reproductive toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2008
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- KL2 due to RA
- Justification for type of information:
- Refer to the section 13 of IUCLID dataset for details on the read across justification. The algae study with the read across substance is considered sufficient to fulfil the information requirements as further explained in the provided endpoint summary.
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 416 (Two-Generation Reproduction Toxicity Study)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Route of administration:
- oral: feed
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- - Exposure period: about 18 wk.
P0 and P1:
Premating exposure period (males): 10 wk.
Premating exposure period (females): 10 wk.
- Duration of test: P0 pre-mating 10 wk, until F2 weaning. - Frequency of treatment:
- Continuously
- Details on study schedule:
- Groups of 25 male and 25 female Sprague-Dawley rats were administered the test substance (purity 49.9%) at levels of 0, 500, 2000 or 4000 ppm in their diet over a period of 10 wk before mating, 2 wk during mating, and until after weaning of the pups (total period 18 wk). From every litter one or two pups were selected to again obtain 25 animals per sex and dose group for the F1 generation. These animals were similarly treated as the parent (P1) animals throughout premating, mating, pregnancy until sacrifice, after weaning of F2 progeny.
- Remarks:
- Doses / Concentrations:
1000, 2000 and 4000 ppm of test substance - No. of animals per sex per dose:
- 25
- Control animals:
- yes, concurrent vehicle
- Parental animals: Observations and examinations:
- - Examination of P0 and P1 generation:
Clinical signs and mortality were checked daily. Food consumption and body weight were recorded at designated intervals. Males and females were paired for a 2-wk period, until mating was obtained. The P1 females were allowed to deliver normally, and rear their progeny. Pregnancy and litter parameters were recorded.
- During lactation, the pups (F1 generation) were observed daily for survival and clinical signs; body weight was recorded at designated intervals; the sex-ratio was recorded. On Day 4 post-partum, the size of each litter was adjusted to obtain eight pups per litter (four males and four females).
- Reflex development was assessed at designated time-points. - Sperm parameters (parental animals):
- Epididymal and testicular sperm parameters were evaluated for both P0 and P1 males.
- Litter observations:
- Examination of F1/P1 generation:
- On Day 22 post-partum, one male and one female pup per litter were selected to constitute the F1/P1 generation, which comprised 25 males and 25 females per group. The F1/P1 animals were observed daily for clinical signs and mortality. Body weight and food consumption were recorded once a week. Sexual development of both males and females was assessed.
- Neurobehavioural tests were conducted at designated intervals to assess auditory and visual functions. Spontaneous locomotor activity was also evaluated when the animals were between 7 and 8 wk old.
- After sexual maturity, F1 male and F1 female animals were paired. The F1 females were allowed to deliver normally, and rear their progeny. Pregnancy and litter parameters were recorded. During lactation, the pups (F2 generation) were observed daily for survival and clinical signs; body weight was recorded at designated intervals; the sex-ratio was recorded. On day 4 post-partum, the size of each litter was adjusted to obtain eight pups per litter (four males and four females).
- Reflex development was assessed at designated time-points. - Postmortem examinations (parental animals):
- Terminal examination of P0 and P1 animals:
- After weaning of their respective progeny, P0 and P1 parent males and females were sacrificed. Designated organs were weighed for P0 and P1 parents, as well as brain, spleen and thymus of one pup per sex per litter of each generation.
- Epididymal and testicular sperm parameters were evaluated for both P0 and P1 males.
- A macroscopic post-mortem examination was performed on all P0 and P1 parent males and females. Any pups which died or were killed prematurely during the lactation period were also submitted for a macroscopic post-mortem examination. Macroscopic lesions, reproductive organs, adrenals and pituitary glands were sampled in all parent animals. A microscopic examination was performed on macroscopic lesions, reproductive organs, adrenals, and pituitary glands of all P0 and P1 parents of the control and high dose groups.
- Particularly detailed histopathological examinations were performed for the ovaries and the testes. - Postmortem examinations (offspring):
- - A macroscopic post-mortem examination was performed on three pups per sex and per litter of each P0 and P1 (F1 and F2 generation) females killed at weaning. Any pups which died or were killed prematurely during the lactation period were also submitted for a macroscopic post-mortem examination. In all pups, the macroscopic lesions were preserved.
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, a slightly lower mean body weight gain was recorded during most of the dosing period in both parental males and females (and was associated with reduced liver weights).
- At 2000 and 500 ppm, a marginally to slightly lower body weight gain was noted over all the dosing period for the males. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, a slightly to moderately lower mean food consumption was recorded during most of the dosing period in both parental males and females.
- At 2000 and 500 ppm, a marginally to slightly lower mean food consumption was noted over all the dosing period for the males. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- - At 4000 and 2000 ppm, no effects were noted at histopathological examination of sexual organs.
- Histopathological findings: neoplastic:
- not examined
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- no effects observed
- Description (incidence and severity):
- - At 4000 and 2000 ppm, no effects were noted on sperm parameters.
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- - At 4000 ppm, slightly lower pup body weight was observed (with lower spleen weights).
- At 2000 ppm, no effects were observed on parental fertility as assessed by normal mating, gestation and delivery.
- At 500 ppm, no effects were noted on mating, fertility, gestation, fecundity or delivery of either generation or on development of their progeny. - Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic toxicity
- Effect level:
- 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- organ weights and organ / body weight ratios
- gross pathology
- Remarks on result:
- other: the effect level ranged from 16 to 25 mg/kg bw/day
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- reproductive toxicity
- Effect level:
- 2 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reproductive performance
- Remarks on result:
- other: dose range from 61 to 101 mg/kg bw/day
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 4 000 ppm
- System:
- other: reproductive performance
- Treatment related:
- yes
- Dose response relationship:
- yes
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, a slightly to moderately lower mean body weight gain was recorded during most of the dosing period in both parental males and females (and was associated with reduced liver weights).
- At 2000 ppm, a marginally to slightly lower mean body weight gain was noted.
- At 500 ppm, a marginally to slightly lower mean body weight gain was observed in both sexes. This was associated with lower liver weights of parental males and females. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, a slightly to moderately lower mean food consumption was recorded during most of the dosing period in both parental males and females.
- At 2000 and 500 ppm, a marginally to slightly lower mean food consumption was noted over all the dosing period in both sexes. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, reduced liver weights were observed.
- At 2000 and 500 ppm, lower liver weights in parental animals were recorded. - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, necropsy of these animals revealed dilation of the cecum, colon or ileum in some animals (more marked in F0 parents).
- At 2000 ppm, necropsy of parents revealed dilatation of the cecum in a single animal. - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- - At 4000 and 2000 ppm, no effects were noted at histopathological examination of sexual organs.
- Histopathological findings: neoplastic:
- not examined
- Reproductive function: sperm measures:
- no effects observed
- Description (incidence and severity):
- - At 4000 and 2000 ppm, no effects were noted on sperm parameters.
- Description (incidence and severity):
- - At 4000 ppm, slightly lower pup body weight was observed for each progeny and was associated, for the F2 generation pups, with a reduction in litter size (as a consequence of lower number of implantation sites of P1 females) and a delay in sexual development. Lower spleen weights were also noted for each progeny.
- At 2000 ppm, no effects were noted on parental fertility as assessed by normal mating, gestation and delivery.
- At 500 ppm, no effects were noted on mating, fertility, gestation, fecundity or delivery and development of their progeny. - Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic toxicity
- Effect level:
- 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- organ weights and organ / body weight ratios
- gross pathology
- Remarks on result:
- other: the effect level ranged from 16 to 25 mg/kg bw/day
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- reproductive toxicity
- Effect level:
- 2 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- organ weights and organ / body weight ratios
- gross pathology
- Remarks on result:
- other: dose range from 61 to 101 mg/kg bw/day
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 4 000 ppm
- System:
- other: reproductive performance
- Treatment related:
- yes
- Dose response relationship:
- yes
- Clinical signs:
- not examined
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, the litter size at birth was reduced.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, slightly reduced pup body weight was observed. Pup weight gain was also slightly lower during lactation.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, lower spleen weights were noted.
- At 2000 ppm, except for a marginally lower spleen weight of the progeny, no other effects were noted on their development. - Gross pathological findings:
- no effects observed
- Histopathological findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- general toxicity
- Generation:
- F1
- Effect level:
- 2 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- organ weights and organ / body weight ratios
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- developmental toxicity
- Generation:
- F1
- Effect level:
- 2 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- organ weights and organ / body weight ratios
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 4 000 ppm
- System:
- other: body weight and organs weight
- Organ:
- spleen
- Treatment related:
- yes
- Dose response relationship:
- yes
- Clinical signs:
- not examined
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, the litter size at birth were reduced (as a consequence of lower number of implantation sites of F1 parent females).
- At 2000 ppm, no effects were seen in F2 offspring regarding pup survival until weaning. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, slightly lower pup body weight was observed. The pup weight gain was slightly reduced during lactation,
- At 2000 ppm, no effects were seen regarding pup development. - Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- - At 4000 ppm, lower spleen weights were noted.
- At 2000 ppm, except for a marginally lower spleen weight, no other effects were noted on their development. - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- At 4000 ppm, dilatation of the caecum with faeces was observed in 4/25 males and 2/25 females.
At 2000 ppm, no effects were seen regarding pup development and after sacrifice at weaning. - Histopathological findings:
- not examined
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- general / developmental toxicity
- Generation:
- F2
- Effect level:
- 2 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- sexual maturation
- mortality
- body weight and weight gain
- organ weights and organ / body weight ratios
- gross pathology
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- general / developmental toxicity
- Generation:
- F2
- Effect level:
- 4 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- sexual maturation
- mortality
- body weight and weight gain
- organ weights and organ / body weight ratios
- gross pathology
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 4 000 ppm
- System:
- other: spleen weight
- Treatment related:
- yes
- Dose response relationship:
- yes
- Key result
- Reproductive effects observed:
- yes
- Lowest effective dose / conc.:
- 2 000 ppm
- Treatment related:
- yes
- Relation to other toxic effects:
- reproductive effects as a secondary non-specific consequence of other toxic effects
- Dose response relationship:
- yes
- Conclusions:
- Based on the results of the study, the rat NOEL for parental toxicity is considered to be 500 ppm for the male and the female animals. The rat NOEL for mating behaviour, fertility and gestation of each generation and for development, growth and survival of each progeny is established at 2,000 ppm (61 to 101 mg/kg bw/day (nominal) (equivalent to 30.5 to 50.5 mg a.i./kg bw/day and 96 to 123 mg/kg bw/day (nominal) (equivalent to 48 to 61.5 mg a.i./kg bw/day for the F0 and F1 generation respectively))
- Executive summary:
A study was conducted to determine the toxicity to reproduction of the read across substance, C12-C16 ADBAC (active: 49.9%), according to OECD Guideline 416, in compliance with GLP. In this two-generation study, the substance was administered in the diet to male and female Sprague Dawley rats at dose levels of 0, 500, 2,000 and 4,000 ppm (purity 49.9%) (corresponding to 0 mg (a.i.)/kg bw/day, 16-25 and 24-31 mg/kg bw/day or 8-12.5 and 12-15.5 mg a.i./kg bw/day in males and females, 61-101 and 96-123 mg/kg bw/day or 30.5-50 and 48 to 61.5 mg a.i./kg bw/day in males and females and 123-208 and 202-252 mg/kg bw/day or 61-104 and 101-126 mg a.i./kg bw/day in males and females, respectively). Doses were administered before and throughout mating and gestation until the end of the lactation period in both P0 and P1 generations. At 2,000 ppm, P0 (males) and P1 (both sexes) showed marginally to slightly lower body weight gains and reduced food consumption. Necropsy of parents of both generations revealed dilatation of the caecum in some animals. This was associated with lower liver weights in parental animals of both generations. At 4,000 ppm, in P0 and P1 generations, number of implantation sites and litter size at birth were reduced. The progenies (F1 and F2) also showed lower pup weights. Pup weight gain was slightly lower during lactation. The weight of the spleen was also reduced. Upon necropsy, dilatation of the caecum with faeces was observed in 4/25 males and 2/25 females in F2. Treatment with the test substance had no effect on mating, fertility and behavioural parameters in P0 and P1 parental Sprague-Dawley rats at treatment levels up to 2,000 ppm. No effect was recorded on litter parameters and on pre- and post-natal development of either generation at 2,000 ppm. Under the conditions of the study, the rat NOEL for parental toxicity was at 500 ppm for the male and the female animals. The rat NOEL for mating behaviour, fertility and gestation of each generation and for development, growth and survival of each progeny was established at 2,000 ppm (61 to 101 mg/kg bw/day (nominal) (equivalent to 30.5 to 50.5 mg a.i./kg bw/day and 96 to 123 mg/kg bw/day (nominal) (equivalent to 48 to 61.5 mg a.i./kg bw/day for the F0 and F1 generation respectively)) (Foulon, 2008). Based on the results of the read across study, similar NOAEL for parental and reproductive/development toxicity can be considered for the test substance, C18 ADBAC.
Reference
The mean achieved dosages of the test
substance for the dose-levels of 500, 2000 and 4000 ppm of test
substance were as follows:
F0 generation
- males (Days 1 to 106): 16, 61 and 123 mg/kg bw/day, respectively,
- females:
during premating period (Days 1 to 71): 19, 74 and 154
mg/kg bw/day, respectively,
during pregnancy period (Days 0 to 20 p.c.): 18, 69 and 145 mg/kg
bw/day, respectively,
during lactation period (Days 1 to 21 p.p.): 37, 159 and 326 mg/kg
bw/day, respectively.
F1 generation
- males (Days 1 to 120): 24, 96 and 202 mg/kg bw/day, respectively,
- females:
during premating period (Days 1 to 64): 32, 127 and 269 mg/kg
bw/day, respectively,
during pregnancy period (Days 0 to 20 p.c.): 21, 83 and 164 mg/kg
bw/day, respectively,
during lactation period (Days 1 to 21 p.p.): 41, 162 and 323 mg/kg
bw/day, respectively.
The actual intake of test substance for both males and females given
500, 2000 and 4000 ppm throughout the study is approximately
16-25, 61-101 and 123-208 mg/kg bw/day, respectively for the
F0 generation and 24-31, 96-123 and 202-252 mg/kg bw/day for
the F1 generation.
Effect on fertility: via oral route
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 30.5 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Information requirement for this tonnage band is sufficiently met with the available data.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
A study was conducted to determine the toxicity to reproduction of the read across substance, C12-C16 ADBAC (active 49.9%), according to OECD Guideline 416, in compliance with GLP. In this two-generation study, the substance was administered in the diet to male and female Sprague Dawley rats at dose levels of 0, 500, 2,000 and 4,000 ppm (purity 49.9%) (corresponding to 0 mg (a.i.)/kg bw/day, 16-25 and 24-31 mg/kg bw/day or 8-12.5 and 12-15.5 mg a.i./kg bw/day in males and females, 61-101 and 96-123 mg/kg bw/day or 30.5-50 and 48 to 61.5 mg a.i./kg bw/day in males and females and 123-208 and 202-252 mg/kg bw/day or 61-104 and 101-126 mg a.i./kg bw/day in males and females, respectively). Doses were administered before and throughout mating and gestation until the end of the lactation period in both P0 and P1 generations. At 2,000 ppm, P0 (males) and P1 (both sexes) showed marginally to slightly lower body weight gains and reduced food consumption. Necropsy of parents of both generations revealed dilatation of the caecum in some animals. This was associated with lower liver weights in parental animals of both generations. At 4,000 ppm, in P0 and P1 generations, number of implantation sites and litter size at birth were reduced. The progenies (F1 and F2) also showed lower pup weights. Pup weight gain was slightly lower during lactation. The weight of the spleen was also reduced. Upon necropsy, dilatation of the caecum with faeces was observed in 4/25 males and 2/25 females in F2. Treatment with the test substance had no effect on mating, fertility and behavioural parameters in P0 and P1 parental Sprague-Dawley rats at treatment levels up to 2,000 ppm. No effect was recorded on litter parameters and on pre- and post-natal development of either generation at 2,000 ppm. Under the conditions of the study, the rat NOEL for parental toxicity was at 500 ppm for the male and the female animals. The rat NOEL for mating behaviour, fertility and gestation of each generation and for development, growth and survival of each progeny was established at 2,000 ppm (i.e., equivalent to 30.5 to 50.5 mg a.i./kg bw/day and 48 to 61.5 mg a.i./kg bw/day for the F0 and F1 generation respectively) (Foulon, 2008). Based on the results of the read across study, similar NOELs for parental and reproductive/development toxicity can be considered for the test substance, C18 ADBAC.
Effects on developmental toxicity
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the results of the read across study, the test substance, C18 ADBAC, is concluded not to warrant classification for reproductive toxicity according to EU CLP criteria (Regulation 1272/2008/EC).
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)